Providing high quality reagents for 3D printing human tissue models 

OUR BIOINK TECHNOLOGY

Compatible with multiple bioprinters

High cell viability post printing

Beta tested by industry leaders

Xeno-free

Reduces time and labor costs

Designed for use with fragile cells

AxB1_edited.jpg

AWARDS & RECOGNITION

 
 

MEET THE TEAM

 

Dr. Stephanie Willerth
~
CEO

  • LinkedIn

Dr. Willerth is a full professor of Biomedical Engineering who runs an active research group that investigates how to engineer neural tissue from pluripotent stem cells. Her research group has developed many types of biomaterial scaffolds for promoting the differentiation of induced pluripotent
stem cells (iPSCs) into neural phenotypes for tissue engineering applications, such as screening the toxicity of drugs, learning about how tissues form during development and replacing dysfunctional tissues. She founded Axolotl Biosciences with the goal of bioprinting neural tissues easily accessible to scientists and engineering from a range of backgrounds.

Laura-Crop.jpg

Dr. Laura De La Vega
~

Co-Founder

  • LinkedIn

Dr. Laura De La Vega is a scientist and bioengineer who's passionate about basic, translational science and innovative technologies. She holds expertise in the fields of stem cells, biomaterials, and biotechnology involving the development of technological applications using biological systems. She completed her PhD at the University of Victoria where she developed novel techniques for engineering neural tissue under the direction of Dr. Willerth. Her goal in co-founding Axolotl Biosciences is to optimize bioinks for multiple bioprinting platforms and address customer needs within the 3D bioprinting industry.

Laila Abelseth
~
Co-Founder

  • LinkedIn

Laila completed an Undergraduate Degree in Biomedical Engineering at the University of Victoria. During the final year of her degree she focused on cell culture and tissue engineering by completing two work terms in Dr.Willerth's lab and incorporating
tissue engineering into her honours and final capstone projects. Through her work with Axolotl Biosciences, she wants to contribute to advancements in tissue engineering and biological research which will hopefully lead to improved healthcare.

 

SUPPORTED BY:

BioTalent_Logo_CMYK_bilEF_NoTag-002-scal
46fa9493-63e5-4187-81b9-3e62e6c5aa87.jpeg
irap-750x459-removebg-preview.png
MSFHR_logo.jpg
InnovateBC_Logo.png
AxB4.PNG

PUBLICATIONS

3D printing of neural tissues derived from human induced pluripotent stem cells using a fibrin-based bioink

ACS Biomaterials Science and Engineering. 2018;5(1):234-43

E. Abelseth, L. Abelseth, L. De la Vega, S.T. Beyer, S.J.Wadsworth, S.M. Willerth

Bioprinting a novel glioblastoma tumor model using a fibrin based bioink for drug screening

Materials Today Chemistry. 2019, (12). 78-84

C. Lee, E. Abelseth, L. de la Vega, S.M. Willerth

3D bioprinting human induced pluripotent stem cell-derived neural tissues using a novel lab-on-a-printer technology

Applied Science. 2018. 2018, 8(2414). 1-13

L. De la Vega, D.A. Rosas Gómez, E. Abelseth, L. Abelseth, V.A. da Silva, S.M. Willerth

3D bioprinting pluripotent stem cell derived neural tissues using a novel fibrin bioink containing drug releasing microspheres

Frontiers in Bioengineering and Biotechnology. 2020, 8(57)

R. Sharma, I.P.M. Smits, L. De la Vega, C. Lee, S.M. Willerth

Novel N-cadherin antagonist causes glioblastoma cell death in a 3D bioprinted co-culture model

Biochemical and Biophysical Research Communications. 2020. 2020, 527(2),162-168

I.P.M. Smits, O.W. Blaschuk, S.M. Willerth

3D bioprinting human pluripotent stem cells and drug releasing microspheres to produce responsive neural tissue 

Advanced NanoBioMed Research. 2000077. 1-16.

L. De la Vega, L. Abelseth, R. Sharma, J. Triviño-Paredes, M. Restan, S.M. Willerth

 
Composite (RGB)_M-_scalebar (1).png
 
 

CHECK OUT OUR SOCIAL MEDIA

CONTACT US

If you are interested in beta testing our bioink with your bioprinting system or cell type, please fill out the form below and our development team will be in contact with you.